Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Phase 3 clinical trials complete for ‘superpotent’ corticosteroid ➤ New rapid, quantitative MMP-9 tear test ➤ First pediatric patient dosed with experimental gene-editing therapy for Leber congenital amaurosis ➤ Study: Comparison of NCX 470 to latanoprost for glaucoma ➤ Collaborations for inherited retinal diseases ➤ ASCRS news and events
➤ Topline data from Phase 3 trial of presbyopia-correcting drop ➤ FDA gives 510(K) approval to updated neuromodulation therapy for increased tear production ➤ Enrollment complete for Phase 3 trial of reproxalap ➤ DME trial to focus on underrepresented patient populations ➤ BLA submitted to FDA for wet AMD therapy ➤ Companies collaborate to further develop gene therapy for retinal disease ➤ ASCRS news and events
➤ FDA approves new ICL ➤ Home tonometer receives 510(k) clearance ➤ First patient treated in what will be the largest standalone MIGS clinical trial ➤ Topline results from second Phase 3 trial of mydriasis-reversing drug ➤ ASCRS news and events
➤ Launch of Phase 3 clinical trial for presbyopia drop candidate ➤ Topline results for investigational dry eye therapy ➤ Positive findings for photobiomodulation dry AMD treatment ➤ Enrollment completed for investigational oral diabetic retinopathy therapy ➤ Longer-term data from Phase 3 studies evaluating geographic atrophy therapy released ➤ Orphan drug designation granted to investigational retinitis pigmentosa treatment ➤ ASCRS news and events
➤ Results from pivotal amblyopia trial ➤ Phase 2 clinical program for third-generation keratoconus treatment ➤ Study compares tolerability of standard drop vs. novel drug delivery device ➤ Phase 3 clinical studies for investigational presbyopia drop complete ➤ Orphan drug designation granted for fungal keratitis treatment ➤ Full rights regained for investigational dry AMD therapy ➤ ASCRS news and events
➤ Launch of IOL made with new ‘glistening-free’ material ➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group ➤ Acquisition of electrophysiology medical device company ➤ Licensing of investigational neuroprotective drug ➤ ASCRS news and events
➤ FDA approves first drug-eluting contact lens ➤ FDA accepts 510(k) submission for new femto-phaco device ➤ Phase 2 study begins to evaluate an immunomodulatory agent for dry eye ➤ Licensing agreement for optic nerve-protective therapy ➤ Phase 3 study to evaluate protein replacement solution for dry eye ➤ Study: Impact of age on SMILE outcomes ➤ ASCRS news and events
➤ FDA accepts NDA for anesthesia, pain management drug ➤ Five-year results with intracanalicular microstent ➤ Request for information about ocular imaging ➤ Post-hoc analysis of NMOSD treatment ➤ Investigational visual prosthesis implanted in blind patient ➤ ASCRS news and events
➤ Nerve growth factor being studied as a possible treatment for Sjogren’s-related dry eye ➤ Investigational RNA therapy doesn’t meet primary endpoint ➤ Phase 1 clinical trial for bioerodible, sustained anti-VEGF delivery ➤ Positive interim data for diabetic retinopathy treatment ➤ Positive results in trial for high-dose aflibercept ➤ Additional Phase 3 trial data for Beovu in DME ➤ ASCRS news and events
➤ FDA approves generic Restasis ➤ Phase 3 trial for novel, preservative-free drug delivery platform ➤ Enrollment complete for Phase 3 blepharitis trial ➤ Enrollment complete for Phase 3 mydriasis reversal study ➤ Path forward for resubmission of drug-device combination product ➤ ‘Immunity and Inflammation in the Anterior Segment of the Eye’ report ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.